International Consensus Guidelines on the Implementation and Monitoring of Vosoritide Therapy in Individuals with Achondroplasia

Since the approval of vosoritide in 2021, a need was created for a treatment guideline for support clinicians. An international collaborative of leading experts and patient advocates was formed to develop a consensus statement to provide recommendations across the treatment pathway, from starting treatment with vosoritide through ongoing monitoring and evaluation, to stopping vosoritide and ongoing monitoring following cessation. The guidelines recommend a set of requirements and practical framework for professionals and health services worldwide regarding the use of vosoritide to treat infants, children and young people with achondroplasia. This consensus is a supplement to already established consensus guidelines for the management and care of individuals with achondroplasia.